Currently, immunotherapies for CRC such as programmed cell death protein 1 (PD-1) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blockers act mainly through T cells (Makaremi, et al., 2021), while beneficial bacteria act synergistically with immune checkpoint blockade (ICB) by activating immune cells and regulating cytokine secretion. This evidence concerns the gene CTLA4 and colorectal carcinoma.